-
PET/MRI Scanning Technique Devised to Track 3-D Motion
Update, 25 July 2013. We learned today that Jinsong Ouyang at Mass General Hospital is the principal investigator on the project and led the research, not Chuan Huang, who presented the findings. Others working on the project include Jerome Ackerman, Yoann Petibon, Thomas Brady, and Georges El Fakhri. Researchers at Massachusetts General Hospital and Harvard…
-
Kidney Disease Technology Start-Up Lands $9.5M Venture Funds
TVA Medical Inc., a developer of devices in Austin, Texas to treat end-stage renal disease, secured $9.5 million in series B venture funds, the second round of financing after initial start-up. Austin-based S3 Ventures, an early-stage venture capital company, led the round with TriStar Technology Ventures and existing investor Santé Ventures. End-stage renal disease occurs…
-
Science Business Content Partner: The Life Sciences Report
Science Business is pleased to offer a new feature, the latest entries from the investment newsletter, The Life Sciences Report, published by Streetwise Reports. The Life Sciences Report features interviews with investment experts in biotechnology, pharmaceuticals, medical devices, and diagnostics. Science Business aims to provide breaking news developments in the science and business of the…
-
National Lab Develops Solar Photosynthesis Testing Device
Researchers at Lawrence Berkeley National Laboratory in California developed a device to test on a small scale electrochemical solar-energy conversion methods for future fuel cell and artificial photosynthesis technologies. The team led by Joel Ager and Rachel Segalman from the Berkeley Lab’s materials science division and Joint Center for Artificial Photosynthesis published its findings in…
-
AstraZeneca Acquires Respiratory Disease Therapy Developer
The global pharmaceutical company AstraZeneca is buying Pearl Therapeutics in Redwood City, California, a developer of treatments for chronic respiratory diseases. The deal is valued initially at $560 million, but has a total potential value of $1.15 billion, adding in subsequent milestone and royalty payments. The seven year-old Pearl Therapeutics develops small-molecule treatments for chronic…
-
FDA Clears Sanofi Four-Strain Flu Vaccine for Adults, Kids
Sanofi Pasteur, the vaccine division of the global pharmaceutical company Sanofi, says the Food and Drug Administration cleared for sale in the U.S. its Fluzone Quadrivalent vaccine that covers four influenza strains. The FDA action, says the company, will make the vaccine available for infants, adolescents, and adults. The Centers for Disease Control and Prevention…
-
St. Jude Medical Invests in Pain Therapy Device Developer
Medical device manufacturer St. Jude Medical in St. Paul, Minnesota is investing $40 million in pain therapy systems developer Spinal Modulation Inc. in Menlo Park, California. The equity investment deal, says St. Jude Medical, includes an option for the outright purchase of the privately-owned Spinal Modulation. Under the agreement, St. Jude Medical becomes the exclusive…
-
Dana-Farber, Foundation Partner on Expanding Clinical Trials
Dana-Farber Cancer Institute in Boston and Leukemia & Lymphoma Society (LLS) in New York are collaborating on opening new sites for clinical trials to test blood cancer therapies. LLS is investing $1,050,000 over three years in the project. The Blood Cancer Research Partnership aims to make it easier for patients to take part in clinical…
-
University Patents, Licenses Cattle Feed Supplement
Kansas State University in Manhattan received a patent and licensed a nutritional supplement for cattle feed developed by one of its faculty members. Research by animal sciences professor Jim Drouillard led to development of a supplement that improves absorption of omega-3 fatty acids beneficial to livestock, which Kansas State patented earlier this year and licensed…
-
First Bioengineered Vein Implanted for U.S. Dialysis Patient
Yesterday, a kidney dialysis patient at Duke University Hospital in Durham, North Carolina was the first in the U.S. to receive a new bioengineered blood vessel developed by a Duke University spin-off company. The patient, a 62 year-old man from Danville, Virginia with kidney failure received in his arm the engineered blood vessel made with…